Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation No phase listed Observational

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

ClinicalTrials.gov ID: NCT06270719

Public ClinicalTrials.gov record NCT06270719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, prospective, observational Phase 4 study including a post marketing safety requirement, designed to collect both medical history data and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec (ELEVIDYS) as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at the time of study enrollment in routine clinical practice.

Study identification

NCT ID
NCT06270719
Recruitment status
Enrolling by invitation
Study type
Observational
Phase
Not listed
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

Genetic · Drug

Eligibility (public fields only)

Age range
4 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 7, 2024 (Actual)
Primary completion
Dec 31, 2028 (Estimated)
Completion
Dec 31, 2038 (Estimated)
Last update posted
Oct 23, 2026

2024 – 2038

United States locations

U.S. sites
29
U.S. states
24
U.S. cities
29
Facility City State ZIP Site status
Children's of Alabama Birmingham Alabama 35233-1701 —
Arkansas Children's Hospital Little Rock Arkansas 72202 —
Children's Hospital Los Angeles Los Angeles California 90027 —
University of Colorado - PPDS Aurora Colorado 80045 —
Connecticut Children's Medical Center - Hartford Hartford Connecticut 06106-3322 —
Children's National Washington D.C. District of Columbia 20010 —
Nicklaus Children's Hospital Miami Florida 33155 —
Nemours Children's Hospital - Orlando Orlando Florida 32827 —
All Children's Research Institute, Inc St. Petersburg Florida 33701 —
Ann and Robert H Lurie Childrens Hospital of Chicago Chicago Illinois 60611-2991 —
Indiana Clinical and Translational Science Institute Indianapolis Indiana 46202 —
University of Kansas Medical Center Kansas City Kansas 66160 —
Norton Children's Neuroscience Institute - Louisville Louisville Kentucky 40202 —
Boston Children's Hospital Boston Massachusetts 02115 —
University of Michigan Ann Arbor Michigan 48109 —
UNM Clinical and Translational Science Center Albuquerque New Mexico 87131-0001 —
Stony Brook Medicine Advanced Specialty Care Stony Brook New York 11794-3369 —
Duke Lenox Baker Children's Hospital Durham North Carolina 27705-4504 —
Childrens Hospital Medical Center of Akron Akron Ohio 44308 —
OHSU Healthcare (Oregon Health and Science University) Portland Oregon 97239 —
Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania 17033 —
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 —
Vanderbilt University Medical Center Nashville Tennessee 37232 —
Cook Children's Hospital Fort Worth Texas 76104 —
University of Virginia Charlottesville Virginia 22903 —
Children's Hospital of the King's Daughters Norfolk Virginia 23507 —
Seattle Children's Hospital Seattle Washington 98105 —
The Board of Regents of the University of Wisconsin Madison Wisconsin 53715-1218 —
The Medical College of Wisconsin Milwaukee Wisconsin 53226-4874 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06270719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06270719 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →